Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial
: Background: Most hypertensive renal transplant recipients require two or more antihypertensive medications to achieve blood pressure control. However, which medications must be combined is still a matter of debate. Methods: A prospective randomized open‐label blinded evaluation trial comparing...
Gespeichert in:
Veröffentlicht in: | Clinical transplantation 2007-03, Vol.21 (2), p.277-284 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 284 |
---|---|
container_issue | 2 |
container_start_page | 277 |
container_title | Clinical transplantation |
container_volume | 21 |
creator | Halimi, Jean-Michel Giraudeau, Bruno Buchler, Matthias Al-Najjar, Azmi Etienne, Isabelle Laouad, Inass Bruyère, Franck Lebranchu, Yvon |
description | : Background: Most hypertensive renal transplant recipients require two or more antihypertensive medications to achieve blood pressure control. However, which medications must be combined is still a matter of debate.
Methods: A prospective randomized open‐label blinded evaluation trial comparing the six‐month effects of the amlodipine–enalapril combination (n = 32) vs. enalapril alone (n = 33) and vs. amlodipine alone (n = 34) on arterial pressure, renal function, albuminuria and tolerability.
Results: At six months, diastolic arterial pressure was more adequately controlled (i.e., |
doi_str_mv | 10.1111/j.1399-0012.2007.00643.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70378322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70378322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5003-8c511c9972fd564ae32977a5009f2d8d40c466fb5b45756d765e0ee1bdc671fd3</originalsourceid><addsrcrecordid>eNqNkE1v1DAQhi0EotvCX0C5wC2pHSd2grigVdkiFRCoFG6WY08kL84Hthd2-fVM2FV7xRdbM-9jjx9CMkYLhutyWzDetjmlrCxKSmVBqah4sX9EVveNx2RFW1riWfAzch7jFquCifopOWOyKmtZNyuSrkbt9Rycv9SDn6yb3QiZmYbOjTq5aczcmJmD8VOcp4C9PAXQCWwWAMksBT3G2esxYcEgDWOKrzOdzQEJMMn9ggwzdhrcH6RScNo_I0967SM8P-0X5Ou7q9v1dX7zafN-_fYmNzWlPG9MzZhpW1n2thaVBl62UmrstX1pG1tRUwnRd3VX4WeElaIGCsA6a4RkveUX5NXxXhzm5w5iUoOLBjyOC9MuKkm5bHhZYrA5Bg1OHQP0Co0MOhwUo2oxrrZqEasWsWoxrv4ZV3tEX5ze2HUD2AfwpBgDL08BHY32PcowLj7kGsFaLpbcm2Put_Nw-O8B1Pr2Cx4Qz4-4iwn297gOP5SQXNbq28eNutu0tLn7_ll94H8BQ5Stww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70378322</pqid></control><display><type>article</type><title>Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Halimi, Jean-Michel ; Giraudeau, Bruno ; Buchler, Matthias ; Al-Najjar, Azmi ; Etienne, Isabelle ; Laouad, Inass ; Bruyère, Franck ; Lebranchu, Yvon</creator><creatorcontrib>Halimi, Jean-Michel ; Giraudeau, Bruno ; Buchler, Matthias ; Al-Najjar, Azmi ; Etienne, Isabelle ; Laouad, Inass ; Bruyère, Franck ; Lebranchu, Yvon</creatorcontrib><description>: Background: Most hypertensive renal transplant recipients require two or more antihypertensive medications to achieve blood pressure control. However, which medications must be combined is still a matter of debate.
Methods: A prospective randomized open‐label blinded evaluation trial comparing the six‐month effects of the amlodipine–enalapril combination (n = 32) vs. enalapril alone (n = 33) and vs. amlodipine alone (n = 34) on arterial pressure, renal function, albuminuria and tolerability.
Results: At six months, diastolic arterial pressure was more adequately controlled (i.e., <90 mmHg) in the combination group than in the amlodipine and enalapril groups (100% vs. 82.4% and 84.8%, respectively, p = 0.038). The same trend was observed for systolic arterial pressure (65.6% vs. 58.8% and 51.5%, NS). The six‐month change in albuminuria was similar in the combination group and in the enalapril group (−64.7% vs. −59.5%); however, patients in the combination group exhibited a greater reduction in albuminuria than in the amlodipine group (−64.7% vs. −29.0%, p = 0.002). As compared with baseline values, serum creatinine and potassium remained unchanged in the combination group, whereas they increased by 9 ± 12 μmol/L (p = 0.01) and by 0.2 ± 0.4 mmol/L (p < 0.01), respectively, in the enalapril group. The cyclosporine trough levels remained unchanged in the combination group, but increased in the amlodipine group.
Conclusion: Angiotensin‐converting enzyme inhibitor (ACEI)–calcium‐channel blocker (CCB) combination controls arterial pressure more adequately than ACEI alone or CCB alone, reduces albuminuria and may prevent the ACEI‐induced initial rise in serum creatinine.</description><identifier>ISSN: 0902-0063</identifier><identifier>EISSN: 1399-0012</identifier><identifier>DOI: 10.1111/j.1399-0012.2007.00643.x</identifier><identifier>PMID: 17425758</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; albuminuria ; Albuminuria - prevention & control ; Amlodipine - therapeutic use ; Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Biological and medical sciences ; Blood Pressure - drug effects ; calcium channel blockers ; Calcium Channel Blockers - therapeutic use ; converting enzyme inhibitors ; Creatinine - blood ; Cyclosporine - blood ; Cyclosporine - therapeutic use ; Drug Therapy, Combination ; Enalapril - therapeutic use ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; hypertension ; Hypertension - prevention & control ; Immunosuppressive Agents - blood ; Immunosuppressive Agents - therapeutic use ; Kidney Transplantation - immunology ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Prospective Studies ; renal function ; renal transplantation ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Tissue, organ and graft immunology ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland</subject><ispartof>Clinical transplantation, 2007-03, Vol.21 (2), p.277-284</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5003-8c511c9972fd564ae32977a5009f2d8d40c466fb5b45756d765e0ee1bdc671fd3</citedby><cites>FETCH-LOGICAL-c5003-8c511c9972fd564ae32977a5009f2d8d40c466fb5b45756d765e0ee1bdc671fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1399-0012.2007.00643.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1399-0012.2007.00643.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18619368$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17425758$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Halimi, Jean-Michel</creatorcontrib><creatorcontrib>Giraudeau, Bruno</creatorcontrib><creatorcontrib>Buchler, Matthias</creatorcontrib><creatorcontrib>Al-Najjar, Azmi</creatorcontrib><creatorcontrib>Etienne, Isabelle</creatorcontrib><creatorcontrib>Laouad, Inass</creatorcontrib><creatorcontrib>Bruyère, Franck</creatorcontrib><creatorcontrib>Lebranchu, Yvon</creatorcontrib><title>Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial</title><title>Clinical transplantation</title><addtitle>Clin Transplant</addtitle><description>: Background: Most hypertensive renal transplant recipients require two or more antihypertensive medications to achieve blood pressure control. However, which medications must be combined is still a matter of debate.
Methods: A prospective randomized open‐label blinded evaluation trial comparing the six‐month effects of the amlodipine–enalapril combination (n = 32) vs. enalapril alone (n = 33) and vs. amlodipine alone (n = 34) on arterial pressure, renal function, albuminuria and tolerability.
Results: At six months, diastolic arterial pressure was more adequately controlled (i.e., <90 mmHg) in the combination group than in the amlodipine and enalapril groups (100% vs. 82.4% and 84.8%, respectively, p = 0.038). The same trend was observed for systolic arterial pressure (65.6% vs. 58.8% and 51.5%, NS). The six‐month change in albuminuria was similar in the combination group and in the enalapril group (−64.7% vs. −59.5%); however, patients in the combination group exhibited a greater reduction in albuminuria than in the amlodipine group (−64.7% vs. −29.0%, p = 0.002). As compared with baseline values, serum creatinine and potassium remained unchanged in the combination group, whereas they increased by 9 ± 12 μmol/L (p = 0.01) and by 0.2 ± 0.4 mmol/L (p < 0.01), respectively, in the enalapril group. The cyclosporine trough levels remained unchanged in the combination group, but increased in the amlodipine group.
Conclusion: Angiotensin‐converting enzyme inhibitor (ACEI)–calcium‐channel blocker (CCB) combination controls arterial pressure more adequately than ACEI alone or CCB alone, reduces albuminuria and may prevent the ACEI‐induced initial rise in serum creatinine.</description><subject>Adult</subject><subject>albuminuria</subject><subject>Albuminuria - prevention & control</subject><subject>Amlodipine - therapeutic use</subject><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>calcium channel blockers</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>converting enzyme inhibitors</subject><subject>Creatinine - blood</subject><subject>Cyclosporine - blood</subject><subject>Cyclosporine - therapeutic use</subject><subject>Drug Therapy, Combination</subject><subject>Enalapril - therapeutic use</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>hypertension</subject><subject>Hypertension - prevention & control</subject><subject>Immunosuppressive Agents - blood</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Kidney Transplantation - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Prospective Studies</subject><subject>renal function</subject><subject>renal transplantation</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Tissue, organ and graft immunology</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Urinary tract. Prostate gland</subject><issn>0902-0063</issn><issn>1399-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1v1DAQhi0EotvCX0C5wC2pHSd2grigVdkiFRCoFG6WY08kL84Hthd2-fVM2FV7xRdbM-9jjx9CMkYLhutyWzDetjmlrCxKSmVBqah4sX9EVveNx2RFW1riWfAzch7jFquCifopOWOyKmtZNyuSrkbt9Rycv9SDn6yb3QiZmYbOjTq5aczcmJmD8VOcp4C9PAXQCWwWAMksBT3G2esxYcEgDWOKrzOdzQEJMMn9ggwzdhrcH6RScNo_I0967SM8P-0X5Ou7q9v1dX7zafN-_fYmNzWlPG9MzZhpW1n2thaVBl62UmrstX1pG1tRUwnRd3VX4WeElaIGCsA6a4RkveUX5NXxXhzm5w5iUoOLBjyOC9MuKkm5bHhZYrA5Bg1OHQP0Co0MOhwUo2oxrrZqEasWsWoxrv4ZV3tEX5ze2HUD2AfwpBgDL08BHY32PcowLj7kGsFaLpbcm2Put_Nw-O8B1Pr2Cx4Qz4-4iwn297gOP5SQXNbq28eNutu0tLn7_ll94H8BQ5Stww</recordid><startdate>200703</startdate><enddate>200703</enddate><creator>Halimi, Jean-Michel</creator><creator>Giraudeau, Bruno</creator><creator>Buchler, Matthias</creator><creator>Al-Najjar, Azmi</creator><creator>Etienne, Isabelle</creator><creator>Laouad, Inass</creator><creator>Bruyère, Franck</creator><creator>Lebranchu, Yvon</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200703</creationdate><title>Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial</title><author>Halimi, Jean-Michel ; Giraudeau, Bruno ; Buchler, Matthias ; Al-Najjar, Azmi ; Etienne, Isabelle ; Laouad, Inass ; Bruyère, Franck ; Lebranchu, Yvon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5003-8c511c9972fd564ae32977a5009f2d8d40c466fb5b45756d765e0ee1bdc671fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>albuminuria</topic><topic>Albuminuria - prevention & control</topic><topic>Amlodipine - therapeutic use</topic><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>calcium channel blockers</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>converting enzyme inhibitors</topic><topic>Creatinine - blood</topic><topic>Cyclosporine - blood</topic><topic>Cyclosporine - therapeutic use</topic><topic>Drug Therapy, Combination</topic><topic>Enalapril - therapeutic use</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>hypertension</topic><topic>Hypertension - prevention & control</topic><topic>Immunosuppressive Agents - blood</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Kidney Transplantation - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Prospective Studies</topic><topic>renal function</topic><topic>renal transplantation</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Tissue, organ and graft immunology</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Halimi, Jean-Michel</creatorcontrib><creatorcontrib>Giraudeau, Bruno</creatorcontrib><creatorcontrib>Buchler, Matthias</creatorcontrib><creatorcontrib>Al-Najjar, Azmi</creatorcontrib><creatorcontrib>Etienne, Isabelle</creatorcontrib><creatorcontrib>Laouad, Inass</creatorcontrib><creatorcontrib>Bruyère, Franck</creatorcontrib><creatorcontrib>Lebranchu, Yvon</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Halimi, Jean-Michel</au><au>Giraudeau, Bruno</au><au>Buchler, Matthias</au><au>Al-Najjar, Azmi</au><au>Etienne, Isabelle</au><au>Laouad, Inass</au><au>Bruyère, Franck</au><au>Lebranchu, Yvon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial</atitle><jtitle>Clinical transplantation</jtitle><addtitle>Clin Transplant</addtitle><date>2007-03</date><risdate>2007</risdate><volume>21</volume><issue>2</issue><spage>277</spage><epage>284</epage><pages>277-284</pages><issn>0902-0063</issn><eissn>1399-0012</eissn><abstract>: Background: Most hypertensive renal transplant recipients require two or more antihypertensive medications to achieve blood pressure control. However, which medications must be combined is still a matter of debate.
Methods: A prospective randomized open‐label blinded evaluation trial comparing the six‐month effects of the amlodipine–enalapril combination (n = 32) vs. enalapril alone (n = 33) and vs. amlodipine alone (n = 34) on arterial pressure, renal function, albuminuria and tolerability.
Results: At six months, diastolic arterial pressure was more adequately controlled (i.e., <90 mmHg) in the combination group than in the amlodipine and enalapril groups (100% vs. 82.4% and 84.8%, respectively, p = 0.038). The same trend was observed for systolic arterial pressure (65.6% vs. 58.8% and 51.5%, NS). The six‐month change in albuminuria was similar in the combination group and in the enalapril group (−64.7% vs. −59.5%); however, patients in the combination group exhibited a greater reduction in albuminuria than in the amlodipine group (−64.7% vs. −29.0%, p = 0.002). As compared with baseline values, serum creatinine and potassium remained unchanged in the combination group, whereas they increased by 9 ± 12 μmol/L (p = 0.01) and by 0.2 ± 0.4 mmol/L (p < 0.01), respectively, in the enalapril group. The cyclosporine trough levels remained unchanged in the combination group, but increased in the amlodipine group.
Conclusion: Angiotensin‐converting enzyme inhibitor (ACEI)–calcium‐channel blocker (CCB) combination controls arterial pressure more adequately than ACEI alone or CCB alone, reduces albuminuria and may prevent the ACEI‐induced initial rise in serum creatinine.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17425758</pmid><doi>10.1111/j.1399-0012.2007.00643.x</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0902-0063 |
ispartof | Clinical transplantation, 2007-03, Vol.21 (2), p.277-284 |
issn | 0902-0063 1399-0012 |
language | eng |
recordid | cdi_proquest_miscellaneous_70378322 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Adult albuminuria Albuminuria - prevention & control Amlodipine - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Biological and medical sciences Blood Pressure - drug effects calcium channel blockers Calcium Channel Blockers - therapeutic use converting enzyme inhibitors Creatinine - blood Cyclosporine - blood Cyclosporine - therapeutic use Drug Therapy, Combination Enalapril - therapeutic use Female Fundamental and applied biological sciences. Psychology Fundamental immunology Humans hypertension Hypertension - prevention & control Immunosuppressive Agents - blood Immunosuppressive Agents - therapeutic use Kidney Transplantation - immunology Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Prospective Studies renal function renal transplantation Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Tissue, organ and graft immunology Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland |
title | Enalapril/amlodipine combination in cyclosporine-treated renal transplant recipients: a prospective randomized trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A28%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enalapril/amlodipine%20combination%20in%20cyclosporine-treated%20renal%20transplant%20recipients:%20a%20prospective%20randomized%20trial&rft.jtitle=Clinical%20transplantation&rft.au=Halimi,%20Jean-Michel&rft.date=2007-03&rft.volume=21&rft.issue=2&rft.spage=277&rft.epage=284&rft.pages=277-284&rft.issn=0902-0063&rft.eissn=1399-0012&rft_id=info:doi/10.1111/j.1399-0012.2007.00643.x&rft_dat=%3Cproquest_cross%3E70378322%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70378322&rft_id=info:pmid/17425758&rfr_iscdi=true |